SHORT COMMUNICATION

ADIPOQ, KCNJ11 and TCF7L2 polymorphisms in type 2 diabetes in Kyrgyz population: A case-control study

Jainagul Isakova1 | Elnura Talaibekova1 | Denis Vinnikov1,2,3 | Iskender Saadanov1 | Nazira Aldasheva1

1Institute of Molecular Biology and Medicine, Bishkek, Kyrgyzstan
2Al-Farabi Kazakh National University, School of Public Health, Almaty, Kazakhstan
3Biological Institute, National Research Tomsk State University, Tomsk, Russian Federation

Correspondence
Jainagul Isakova, Institute of Molecular Biology and Medicine, Bishkek, Kyrgyzstan.
Email: jainagul@mail.ru

Abstract
The aim of this study was to ascertain the polymorphic markers profile of ADIPOQ, KCNJ11 and TCF7L2 genes in Kyrgyz population and to analyze the association of polymorphic markers and combinations of ADIPOQ gene’s G276T locus, KCNJ11 gene’s Glu23Lys locus and TCF7L2 gene’s VS3C>T locus with type two diabetes (T2D) in Kyrgyz population. In this case-control study, 114 T2D patients 109 non-diabetic participants were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Two individual polymorphisms (ADIPOQ rs1501299, KCNJ11 rs5219) were found to be associated with T2D. We found two (Lys23Lys/CC and Glu23Lys/CT) of the overall nine combinations, which were more prevalent in T2D group compared to controls ($\chi^2 = 4.21, P = 0.04$). Lys23Lys/CC combination was associated with a 2.65-fold increased likelihood of T2D (OR = 2.65, 95% CI 1.12-6.28), whereas the Glu23Lys/CT combination also increased such likelihood (OR = 3.88, 95% CI 1.27-11.91). This study demonstrated some association of 276T allele and ADIPOQ gene G276T heterozygous genotype as well as KCNJ11 gene 23Lys allele with T2D in ethnic Kyrgyz, but study results should be interpreted with caution because of the limited statistical power.

KEYWORDS
ADIPOQ, gene, KCNJ11, polymorphism, TCF7L2, type 2 diabetes

1 INTRODUCTION

Diabetes mellitus type 2 (T2D) is one of the major threats to human health because of its high prevalence, persistently growing prevalence and the severity of its late vascular complications if unrecognized and untreated.1 Up to 50% of T2D cases get diagnosis at years 5-7 of the disease, while specific macro- and micro-lesions already exist in 20%-30% patients at that time.1

Genetic predisposition to T2D was studied widely during the last decades.2-4 At present, around 50 candidate genes are considered to increase the likelihood of T2D, of which adiponectin gene (ADIPOQ), potassium channel, inwardly rectifying subfamily J, member 11 (KCNJ11) and transcription factor 7-like 2 (TCF7L2 [IVS3C>T]) may be associated with insulin resistance and β-cells dysfunction.5-13 Carriage of various SNP combinations may explain clinical heterogeneity of this disease. Therefore, the analysis of cumulative SNP contribution in T2D is important.

Large variability in genetic markers of T2D between population groups necessitates studies of ethnicity in genetic risks quantification. Genetic profile of ADIPOQ (c.G276T, rs1501299), KCNJ11 (g.5635A>G, rs5219) and TCF7L2 (g.53341C>T, rs7903146) genes in Kyrgyz population, as well as the association with T2D have never
### Table 1

The distribution of alleles and genotypes of KCNJ11, ADIPOQ and TCF7L2 genes in cases and controls

| Gene/polyorphism (rs) | Genotypes and alleles | T2D cases, n = 114 | Controls, n = 109 | $\chi^2$ | P   | OR  | 95% CI  |
|-----------------------|-----------------------|--------------------|--------------------|--------|-----|------|---------|
| ADIPOQ c.G276T, (rs1501299) | GG                    | 44.7% (51)         | 61.5% (67)         | 6.65   | 0.037 | 0.51 | 0.30-0.87 |
|                       | GT                    | 50.9% (58)         | 36.7% (40)         | 1.80   | 1.05-3.05 |
|                       | TT                    | 4.4% (5)           | 1.8% (2)           | 2.45   | 0.47-12.93 |
|                       | GG                    | 44.7% (51)         | 61.5% (67)         | 6.26   | 0.012 | 0.51 | 0.30-0.87 |
|                       | GT/TT                 | 55.3% (63)         | 38.5% (42)         | 1.97   | 1.16-3.36 |
|                       | TT                    | 4.4% (5)           | 1.8% (2)           | 2.45   | 0.47-12.93 |
|                       | GT/GG                 | 95.6% (109)        | 98.2% (107)        | 0.41   | 0.80-2.15 |
|                       | Allele G              | 70.2%              | 79.8%              | 5.51   | 0.025 | 0.59 | 0.38-0.92 |
|                       | Allele T              | 29.8%              | 20.2%              |       |      |      |         |
| KCNJ11 Glu23Lys, (rs5219) | Lys23Lys                | 20.2% (23)         | 13.8% (15)         | 6.20   | 0.045 | 1.58 | 0.78-3.23 |
|                       | Glu23Lys               | 47.4% (54)         | 37.6% (41)         | 1.49   | 0.87-2.55 |
|                       | Glu23Glu               | 32.5% (37)         | 48.6% (53)         | 0.51   | 0.29-0.87 |
|                       | Glu23Lys/Lys 23Lys     | 67.5% (77)         | 51.4% (56)         | 1.97   | 1.14-3.39 |
|                       | Lys23Lys               | 95.6% (109)        | 98.2% (107)        | 0.41   | 0.80-2.15 |
|                       | Glu23Lys/Glu23Glu      | 67.5% (77)         | 51.4% (56)         | 1.97   | 1.14-3.39 |
|                       | Allele Lys             | 44%                | 32.6%              | 6.01   | 0.019 | 1.62 | 1.10-2.38 |
|                       | Allele Glu             | 56%                | 67.4%              |       |      |      |         |
| TCF7L2 g.53341C>T, (rs7903146) | TT                    | 2.6% (3)           | 3.7% (4)           | 0.50   | 0.772 | 0.71 | 0.16-3.25 |
|                       | CT                    | 17.5% (20)         | 14.7% (16)         | 1.24   | 0.60-2.53 |
|                       | CC                    | 79.8% (91)         | 81.7% (89)         | 0.89   | 0.46-1.73 |
|                       | CC                    | 79.8% (91)         | 81.7% (89)         | 0.12   | 0.730 | 0.89 | 0.46-1.73 |
|                       | CT/TT                 | 20.2% (23)         | 18.3% (20)         | 1.12   | 0.58-2.19 |
|                       | TT                    | 2.6% (3)           | 3.7% (4)           | 0.20   | 0.717 | 0.71 | 0.16-3.25 |
|                       | CT/CC                 | 97.4% (111)        | 96.3% (105)        | 1.41   | 0.31-6.45 |
|                       | Allele T              | 11.4%              | 11.0%              | 0.02   | 0.98  | 1.04 | 0.58-1.87 |
|                       | Allele C              | 88.6%              | 89.0%              | 0.96   | 0.53-1.73 |

Note. T2D: diabetes type 2; OR: odds ratio; CI: confidence interval.

### Table 2

Significant genotype combinations of G276T polymorphic locus of ADIPOQ gene, Glu23Lys locus of KCNJ11 gene and IVS3C>T locus of TCF7L2 gene in predicting the risk of T2D in Kyrgyz population

| Genotype combinations | T2D group n = 114 (%) | Controls n = 109 (%) | OR (95% CI) | $\chi^2$/P |
|-----------------------|-----------------------|--------------------|-------------|------------|
| ADIPOQ (G276T)+KCNJ11 (Glu23Lys) | G276T+Glu23Lys     | 25 (22)           | 13 (12)     | 4.88 (1.93-12.35) | 10.36/0.0013 |
|                       | G276G+Glu23Lys      | 11 (9.6)          | 6 (5.5)     | 4.65 (1.42-15.21) | 5.53/0.019 |
|                       | G276T+Glu23Glu      | 22 (19.3)         | 18 (16.5)   | 3.10 (1.27-7.59)  | 5.28/0.022 |
| ADIPOQ (G276T)+TCF7L2 (IVS3C>T) | G276T+CC           | 48 (42)           | 34 (31)     | 1.97 (1.07-3.61)  | 4.21/0.04 |
|                       | Lys23Lys+CC         | 21 (18)           | 11 (10)     | 2.65 (1.12-6.28)  | 4.13/0.042 |
|                       | Glu23Lys+CT         | 14 (12)           | 5 (5)       | 3.88 (1.27-11.91) | 4.91/0.027 |
| ADIPOQ (G276T)+KCNJ11 (Glu23Lys)+TCF7L2 (IVS3C>T) | G276T/Glu23Lys/CT | 6 (5)           | 1 (1)       | 14.48 (1.52-134.1) | 5.60/0.02 |

Note. T2D: diabetes type 2; OR: odds ratio; CI: confidence interval.
been studied before. The aim of this study was to ascertain the polymorphic markers profile of ADIPOQ, KCNJ11 and TCF7L2 genes in Kyrgyz population and to analyse the association of polymorphic markers and combinations of ADIPOQ gene’s G276T locus, KCNJ11 gene’s Glu23Lys locus and TCF7L2 gene’s VS3C>T locus with T2D in Kyrgyz population.

2 | MATERIALS AND METHODS

This case-control study with the total sample size N = 223 of unrelated participants of Kyrgyz ethnicity comprised 114 patients, including 61 men (53.5%) and 53 women (46.5%) with clinically verified T2D. 109 patients, including 61 (56%) men and 48 (44%) women without T2D, obesity and with normal total cholesterol and glucose were controls. Patients were included in the main group when they had T2D, diagnosed with World Health Organization (WHO, 1999) criteria and the disease duration was at least 1 year since diagnosis. Patients with pregnancy, severe metabolic decompensation and the combination of two metabolic diseases were excluded. Both cases and controls comprised men and women 18 years and older, all of Kyrgyz ethnicity, born on the territory of Kyrgyz Republic and unrelated with each other. The study was approved by the local Institutional Review Board of the Institute of Molecular Biology and Medicine of Kyrgyz Republic (Minutes #11 of January 14, 2016).

Biological material and self-reported demographic data collection complied with ethical requirements and all patients provided informed consent.

DNA was extracted from blood using the standard method of phenol-chloroform extraction. We used PCR-RFLP method to genotype polymorphic loci. We used \( \chi^2 \) with Yates correction to compare the frequency of alleles and genotypes in the polymorphic markers under study with T2D. The study was approved by the local Institutional Review Board of the Institute of Molecular Biology and Medicine of Kyrgyz Republic (Minutes #11 of January 14, 2016). Biological material and self-reported demographic data collection complied with ethical requirements and all patients provided informed consent.

3 | RESULTS

Two individual polymorphisms (ADIPOQ rs1501299, KCNJ11 rs5219) were found to be associated with type 2 diabetes (Table 1). We found statistically significant differences in the distribution of genotypes and alleles of G276T polymorphic marker of ADIPOQ gene between cases and controls. T2D patients had statistically significant greater prevalence of G276T heterozygous genotype \( (\chi^2 = 6.65; \ P = 0.037) \) and 276T allele \( (\chi^2 = 5.51; \ P = 0.025) \) when compared to controls. G276T heterozygous genotype was associated with almost twofold higher risk of T2D \( (OR = 1.8, \ 95\% \ CI \ 1.05-3.05) \), whereas 276T allele yielded the OR 1.68 (95% CI 1.09-2.60). Our sample of 114 cases, OR of G276T genotype 1.8, 37% exposure in controls and 1:1 case:control ratio yielded 59% statistical power. Homozygous genotype G276G was protective against T2D \( (OR = 0.51, \ 95\% \ CI \ 0.30-0.86) \), as was G allele \( (OR = 0.59, \ 95\% \ CI \ 0.38-0.92) \).

With regard to gene KCNJ11 Glu23Lys polymorphic locus, we found higher 23Lys allele prevalence in T2D group (44%) compared to controls (32.6%, \( P = 0.019 \)). T2D risk was 1.62 times greater in those carrying 23Lys allele compared to Glu23 \( (OR = 1.62; \ 95\% \ CI \ 1.10-2.38) \) carriers. Therefore, 23Lys allele of KCNJ11 gene is the allele of higher T2D risk in Kyrgyz population.

ADIPOQ (G276T), KCNJ11 (Glu23Lys) and TCF7L2 (IVS3C>T) genes are located on different chromosomes and are not bound. When standardising genotyping data (z-clasterisation), we found no correlations between the polymorphic loci under study.

We found two- and three-locus gene-gene interactions of ADIPOQ, KCNJ11 and TCF7L2, which were significantly associated with T2D. Three of the total number of nine genotypes were associated with higher risk of T2D with varying effect (Table 2).

Diabetes mellitus type 2 patients had a statistically significant higher prevalence of G276T/CC genotypes combination (42%) compared to controls (31%) (Table 2). G276T/CC combination was associated with a double risk of T2D \( (OR = 1.97, \ 95\% \ CI \ 1.07-3.61) \). When taken separately, the OR of T2D was 1.8 in G276T polymorphic marker carriers and 0.89 in those carrying CC of TCF7L2 gene. We found two (Lys23Lys/CC and Glu23Lys/CT) of the overall nine combinations, which were more prevalent in T2D group compared to controls \( (\chi^2 = 4.21, \ P = 0.04) \). Lys23Lys/CC combination was associated with a 2.65-fold increased likelihood of T2D \( (OR = 2.65, \ 95\% \ CI \ 1.12-6.28) \), whereas the Glu23Lys/CT combination also increased such likelihood \( (OR = 3.88, \ 95\% \ CI \ 1.27-11.91) \). When taken separately, the OR of T2D was 1.49 in Glu23Lys polymorphic marker carriers and 1.24 in those carrying CT of TCF7L2 gene.

4 | DISCUSSION

This study demonstrated some association of 276T allele and ADIPOQ gene G276T heterozygous genotype as well as KCNJ11 gene 23Lys allele with T2D in ethnic Kyrgyz, but study results should be interpreted with caution because of the limited statistical power.

Literature data support the association of KCNJ11 gene 23Lys allele with T2D in the Chinese, Japanese, Koreans, Russians, British, Tunisian, Taiwanese and Iranians.\(^5\,7\) KCNJ11 gene Glu23Lys polymorphic marker’s association with T2D is likely associated with the replacement of glutamate with lysine in the 23rd position of Kir 6.2 protein, which results in suppressed insulin blood secretion as a result of increased ATP-dependent ionic channel activity, membrane potential change and intracellular calcium concentration decrease, which initiates insulin secretion.\(^2\,5\,7\) The association of ADIPOQ gene G276T polymorphic locus with T2D in our study was also previously confirmed in the Japanese and Taiwanese,\(^8\,9\) and such association may be explained with impaired tissue susceptibility to insulin.\(^2\,8\,9\)
TCF7L2 gene IVS3C/T polymorphic locus was not associated with T2D in the current analysis. Asian and Caucasian populations largely differ in the prevalence of IVS3-T allele of TCF7L2 gene IVS3C/T polymorphism. Asian population studies showed lower IVS3-T allele prevalence (5%-15%) as opposed to Caucasian ones (36%-46%), and even up to 50% in African populations. IVS3-T allele prevalence (11%) in Kyrgyz population was somewhat similar to other Asian populations. Literature data support the role of IVS3-T allele of TCF7L2 gene IVS3C/T polymorphic locus with T2D in the European populations. In Asian populations, TCF7L2 gene IVS3C>T polymorphic locus is either not associated with T2D separately or has a weak association.

Studies of genetic background of T2D are vital to timely identify high-risk individuals and to implement a prevention plan in these individuals as well as in general population.

CONFLICT OF INTEREST

The authors confirm that there are no conflicts of interest.

ORCID

Jainagul Isakova http://orcid.org/0000-0002-3681-6939

REFERENCES

1. Zimmet PZ. Diabetes and its drivers: the largest epidemic in human history? Clin Diabetes Endocrinol. 2017;3:1.
2. Cho YS, Lee J-Y, Park KS, et al. Genetics of type 2 diabetes in East Asian populations. Curr Diab Rep. 2012;12:686-696.
3. Qi Q, Hu FB. Genetics of type 2 diabetes in European populations. J Diabetes. 2012;4:203-212.
4. Cook JP, Morris AP. Multi-ethnic genome-wide association study identifies novel locus for type 2 diabetes susceptibility. Eur J Hum Genet. 2016;24:1175.
5. Zhou D, Zhang D, Liu Y, et al. The E23K variation in the KCNJ11 gene is associated with type 2 diabetes in Chinese and East Asian population. J Hum Genet. 2009;54:433-435.
6. Sakamoto Y, Inoue H, Keshavarz P, et al. SNPs in the KCNJ11-ABCC8 gene locus are associated with type 2 diabetes and blood pressure levels in the Japanese population. J Hum Genet. 2007;52:781-793.
7. Koo BK, Cho YM, Park BL, et al. Polymorphisms of KCNJ11 (Kir6.2 gene) are associated with type 2 diabetes and hypertension in the Korean population. Diabet Med. 2007; 24: 178-186.
8. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002;51:536-540.
9. Tsai M-K, Wang H-MD, Shiang J-C, et al. Sequence variants of ADIPOQ and association with type 2 diabetes mellitus in Taiwan Chinese Han population. Sci World J. 2014;2014:1-7.
10. Cauchi S, Meyre D, Dina C, et al. Transcription factor TCF7L2 genetic study in the French population: expression in human β-cells and adipose tissue and strong association with type 2 diabetes. Diabetes. 2006;55:2903-2908.
11. Horikoshi M, Hara K, Ito C, et al. A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia. 2007;50:747-751.
12. Ren Q, Han XY, Wang F, et al. Exon sequencing and association analysis of polymorphisms in TCF7L2 with type 2 diabetes in a Chinese population. Diabetologia. 2008;51:1146-1152.
13. Chang Y-C, Chang T-J, Jiang Y-D, et al. Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes. 2007;56:2631-2637.

How to cite this article: Isakova J, Talaibekova E, Vinnikov D, Saadanov I, Aldasheva N. ADIPOQ, KCNJ11 and TCF7L2 polymorphisms in type 2 diabetes in Kyrgyz population: A case-control study. J Cell Mol Med. 2019;23:1628–1631. https://doi.org/10.1111/jcmm.14061